Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Neurotune’s Phase II trial (8-week, randomized, double-blind, placebo-controlled, parallel group study) will evaluate the safety and efficacy of NT-11624 (dimiracetam) in the treatment of neuropathic pain, a common side effect of antiretroviral medications. The primary objective of the Phase II study is to assess the drug’s safety in patients under polytherapy for HIV. A secondary objective is to estimate the beneficial effect of dimiracetam on the reduction of pain compared to placebo. The Visual Analogue Scale (VAS) and the Total Symptom Score (TSS) will be primarily used to assess the improvement in symptoms after treatment from baseline through to week eight. The study will enroll at least 100 patients with a planned completion of the study in the middle of 2010.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.